BioSpace News Archive

Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of Seres’ VOWST assets that will provide Nestlé Health Science with full VOWST product and related intellectual property rights.

Zomedica Corp. today announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms.

Replimune Group, Inc. today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.

Permira, the global investment firm, and PharmaCord LLC, a leading provider of patient services for the pharmaceutical industry, announced that a company backed by the Permira funds has signed a definitive agreement to make a substantial investment in PharmaCord.

CorMedix Inc. announced that the Center for Medicare & Medicaid Services has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System.

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the “Offering”) of up to 3,000,000 units of the Company, (each a “Unit”) at a price of $0.10 per each Unit for a gross proceeds of up to $300,000.00.

MAIA Biotechnology, Inc. today announced Company highlights and key achievements year-to-date, including recent clinical progress for lead candidate THIO, a potential first-in-class cancer telomere targeting agent in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC).